检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:贾钰铭[1] 雷开键[1] 袁志平[1] 叶序卷[1] 曾令源[2] 张文彬[2] 张伟[3]
机构地区:[1]宜宾市第二人民医院肿瘤科,四川宜宾644000 [2]四川省肿瘤医院,成都610041 [3]中国医学科学院肿瘤医院生物检测中心,北京100021
出 处:《肿瘤预防与治疗》2008年第2期140-142,146,共4页Journal of Cancer Control And Treatment
摘 要:目的:探讨细胞微管促解聚与促聚合药物序贯使用对肿瘤细胞的抑制作用。方法:采用四唑盐(MTT)比色法,检测化疗药物紫杉醇和长春瑞滨对肿瘤细胞株MCF-7、SK-OV3、A549的抑瘤效应。设定紫杉醇组、长春瑞滨组、紫杉醇加长春瑞滨组、先紫杉醇4小时后加长春瑞滨组和先长春瑞滨4小时后加紫杉醇组,药物浓度为100%血浆峰值浓度(PPC),50%PPC,25%PPC,12.5%PPC,6.25%PPC,培养72小时测定。结果:对三种肿瘤细胞株MCF-7,SK-OV3,A549,先加长春瑞滨4小时后加紫杉醇组抑瘤效应均明显优于其他各组(P<0.01),先紫杉醇4小时后加长春瑞滨组抑瘤率并不优于其他组(P>0.1)。结论:在联合使用微管解聚或聚合的化疗药物时,先使用促解聚药物,再使用促聚合药物,对肿瘤细胞的抑制有增效作用。Objective: To investigate the different inhibition effects of different using sequential of microtubule depolymeriza- tlon drug and polymerization drug on tumor cells. Methods: Three tumor cell lines including MCF-7 .SK-OV3.A549 were incubated with paclitaxel( FiX) and/or vinorelbine (NVB) of different concentrations. The cytotoxicity was examined by MTT test after incubation 72 hours. According to different drugs and different sequences added to 96-well tissue culture plates, 5 groups were divided: PTX group ( Group 1 ), NVB group ( Group 2), Frx plus NVB group ( Group 3), PTX first and plus NVB 4-hours-later group ( Group 4), NVB first and plus Frx 4-hour-later group ( Group 5). Drug concentrations were 100% peak plasma concentration ( PPC), 50% PPC, 25% PPC, 12.5% PPC,and 6. 25% PPC. Results: The inhibition effect on the three tumor ceil lines in Group 5 was stronger than those in the other four groups ( P 〈 0. 01 ). And the inhibition effect in Group 4 was not stronger than those in Group 1, Group 2 or Group 3 (P 〉 0. 1 ). Conclusion: Using microtubule depolymerization drug first and then using microtubule pdymerization drug have synergic inhibition effect on tumor cells.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.249